

SUMMARY OF PRODUCT CHARACTERISTICS

Cefotaxime for Injection USP 1 g



1. Name of the Medicinal Product

- 1.1. **Product Name** : Gebetax 1g
- 1.2. **Generic Name** : Cefotaxime for Injection USP 1g
- 1.3. **Strength** : 1g
- 1.4. **Pharmaceutical form** : Dry Powder for Injection

2. Qualitative & Quantitative Composition

Each vial contains:
Sterile Cefotaxime Sodium USP
equivalent to Cefotaxime.....1 g

3. Pharmaceutical Form

Dry Powder for Injection

4. Clinical Particulars

4.1 Therapeutic Indication

1. Cefotaxime is indicated in the treatment of serious infections, either before the infecting organism has been identified or when caused by bacteria of established sensitivity, including:
 - a. Osteomyelitis,
 - b. septicaemia,
 - c. bacterial endocarditis,
 - d. meningitis, and
 - e. peritonitis and
other serious bacterial infections suitable for parenteral antibiotic therapy.
2. Cefotaxime may be used for pre-operative prophylaxis in patients undergoing surgical procedures, that may be classified as contaminated or potentially so.

4.2 Posology and method of administration

Cefotaxime may be administered intravenously by bolus injection or by infusion, or by intramuscular injection. The dosage, route and frequency of administration should be determined by the severity of infection, the sensitivity of causative organisms and condition of the patient. Therapy may be initiated before the results of sensitivity tests are known.

Adults:

The recommended dosage for mild to moderate infections is 1g 12 hourly. However, dosage may be varied according to the severity of the infection, sensitivity of causative

SUMMARY OF PRODUCT CHARACTERISTICS

Cefotaxime for Injection USP 1 g



organisms and condition of the patient. Therapy may be initiated before the results of sensitivity tests are known.

In severe infections dosage may be increased up to 12g daily given in three or four divided doses. For infections caused by sensitive *Pseudomonas* species daily doses of greater than 6g will usually be required.

Children:

The usual dosage range is 100-150mg/kg/day in two to four divided doses. However, in very severe infection doses of up to 200mg/kg/day may be required.

Neonates:

The recommended dosage is 50mg/kg/day in two to four divided doses. In severe infections 150-200mg/kg/day, in divided doses, have been given.

Dosage in renal impairment:

Because of extra-renal elimination, it is only necessary to reduce the dosage of cefotaxime in severe renal failure (GFR <5ml/min = serum creatinine approximately 751 micromol/litre). After an initial loading dose of 1 g, daily dose should be halved without change in the frequency of dosing, i.e. 1 g twelve hourly becomes 0.5 g twelve hourly, 1 g eight hourly becomes 0.5 g eight hourly, 2 g eight hourly becomes 1g eight hourly etc. As in all other patients, dosage may require further adjustment according to the course of the infection and the general condition of the patient.

Dosage in hepatic impairment:

No dosage adjustment is required.

Method of administration

Intravenous and Intramuscular Administration: Reconstitute Cefotaxime with Water for Injections. Shake well until dissolved and then withdraw the entire contents of the vial into the syringe.

For intermittent I.V. injections, the solution must be injected over a period of 3 to 5 minutes. During post-marketing surveillance, potentially life-threatening arrhythmia has been reported in a very few patients who received rapid intravenous administration of Cefotaxime through a central venous catheter.

Cefotaxime and aminoglycosides should not be mixed in the same syringe or perfusion fluid.

4.3 Contraindications

Hypersensitivity to cephalosporins:

In patients with a history of hypersensitivity to Cefotaxime and/or to any component of Cefotaxime for Injection USP1g, a penicillin or to any other type of beta-lactam drug.

For pharmaceutical forms containing lidocaine:

- known history of hypersensitivity to lidocaine or other local anaesthetics of the amide type
- non-paced heart block
- severe heart failure
- administration by the intravenous route
- infants aged less than 30 months of age.

4.4 Special warning and precautions for use

As with other antibiotics, the use of Cefotaxime, especially if prolonged, may result in overgrowth of non susceptible organisms, such as *Enterococcus spp*, *Candida*, *Pseudomonas aeruginosa*. Repeated evaluation of the condition of the patient is essential. If super infection occurs during treatment with cefotaxime, appropriate measures should be taken and specific anti-microbial therapy should be instituted if considered clinically necessary.

Anaphylactic reactions: Preliminary enquiry about hypersensitivity to penicillin and other β -Lactam antibiotics is necessary before prescribing cephalosporins since cross allergy occurs in 5–10% of cases. The use of cefotaxime is strictly contra-indicated in subjects with a previous history of immediate-type hypersensitivity to cephalosporins. Since cross allergy exists between penicillins and cephalosporins, use of the latter should be undertaken with extreme caution in penicillin sensitive subjects. Serious, including fatal hypersensitivity reactions have been reported in patients receiving cefotaxime. If a hypersensitivity reaction occurs, treatment must be stopped.

Serious bullous reactions: Cases of serious bullous skin reactions like Stevens-Johnson syndrome or toxic epidermal necrolysis have been reported with cefotaxime.

Patients should be advised to contact their doctor immediately prior to continuing treatment if skin and/or mucosal reactions occur.

Patients with renal insufficiency: The dosage should be modified according to the creatinine clearance calculated. Patients with severe renal dysfunction should be placed on the dosage schedule recommended under “Posology and Method of Administration”.

Caution should be exercised if cefotaxime is administered together with aminoglycosides or other nephrotoxic drugs. Renal function must be monitored in these patients, the elderly, and those with pre-existing renal impairment.

Haematological reactions: Leukopenia, neutropenia, and more rarely, agranulocytosis may develop during treatment with cefotaxime, particularly if given over long periods.

SUMMARY OF PRODUCT CHARACTERISTICS

Cefotaxime for Injection USP 1 g



For treatment courses lasting longer than 7-10 days, the blood white cell count should be monitored and treatment stopped in the event of neutropenia.

Some cases of eosinophilia and thrombocytopenia, rapidly reversible on stopping treatment, have been reported. Cases of haemolytic anaemia have also been reported.

Sodium intake: The sodium content of cefotaxime (2.09mmol/g) should be taken into account when prescribing to patients requiring sodium restriction.

Clostridium difficile associated disease (e.g. pseudomembranous colitis): Cefotaxime may predispose patients to pseudomembranous colitis. Although any antibiotic may predispose to pseudomembranous colitis, the risk is higher with broad spectrum drugs, such as cephalosporins. This side effect, which may occur more frequently in patients receiving higher doses for prolonged periods, should be considered as potentially serious.

Diarrhoea, particularly if severe and/or persistent, occurring during treatment or in the initial weeks following treatment, may be symptomatic of *Clostridium difficile* associated disease (CDAD). CDAD may range in severity from mild to life threatening, the most severe form of which is pseudo-membranous colitis.

The diagnosis of this rare but possibly fatal condition can be confirmed by endoscopy and/or histology.

It is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of cefotaxime.

If a diagnosis of pseudomembranous colitis is suspected, cefotaxime should be stopped immediately and appropriate specific antibody therapy should be started without delay.

Clostridium difficile associated disease can be favoured by faecal stasis.

Medicinal products that inhibit peristalsis should not be given.

Neurotoxicity: High doses of beta-lactam antibiotics, including cefotaxime, particularly in patients with renal insufficiency, may result in encephalopathy (e.g. impairment of consciousness, abnormal movements and convulsions).

Patients should be advised to contact their doctor immediately prior to continuing treatment if such reactions occur.

Effects on Laboratory Tests: As with other cephalosporins a positive Coombs' test has been found in some patients treated with cefotaxime. This phenomenon can interfere with the cross-matching of blood.

Urinary glucose testing with non-specific reducing agents may yield false-positive results. This phenomenon is not seen when a glucose-oxydase specific method is used.

4.5 Interaction with other medicinal products and other forms of interaction

Aminoglycoside antibiotics and diuretics: As with other cephalosporins, cefotaxime may potentiate the nephrotoxic effects of nephrotoxic drugs such as aminoglycosides or potent diuretics (e.g. furosemide). Renal function must be monitored.

SUMMARY OF PRODUCT CHARACTERISTICS

Cefotaxime for Injection USP 1 g



Uricosurics: Probenecid interferes with renal tubular transfer of cefotaxime, thereby increasing cefotaxime exposure about 2-fold and reducing renal clearance to about half at therapeutic doses. Due to the large therapeutic index of cefotaxime, no dosage adjustment is needed in patients with normal renal function. Dosage adjustment may be needed in patients with renal impairment.

Interference with Laboratory Tests: A false positive Coombs test may be seen during treatment with cephalosporins. This phenomenon may occur during treatment with cefotaxime and can interfere with blood cross-matching.

A false positive reaction to urinary glucose may occur with copper reduction methods (Benedict's, Fehling's or Clinitest) but not with the use of specific glucose oxidase methods.

There is a potential for mezlocillin and azlocillin to reduce the clearance of cefotaxime.

4.6 Pregnancy and lactation

Pregnancy: The safety of cefotaxime has not been established in human pregnancy.

Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. There are, however, no adequate and well controlled studies in pregnant women.

Cefotaxime crosses the placental barrier. Therefore, cefotaxime should not be used during pregnancy unless the anticipated benefit outweighs any potential risks.

Lactation: Cefotaxime passes into human breast milk in small amounts and is usually compatible with breast feeding, but careful monitoring of the infant is recommended.

Effects on the physiological intestinal flora of the breast-fed infant leading to diarrhoea, colonisation by yeast-like fungi, and sensitisation of the infant cannot be excluded.

Therefore, a decision must be made whether to discontinue breast-feeding or to discontinue therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.

4.7 Effects on ability to drive and use machines

Cefotaxime has been associated with dizziness, which may affect the ability to drive or operate machinery.

There is no evidence that cefotaxime directly impairs the ability to drive or to operate machines. High doses of cefotaxime, particularly in patients with renal insufficiency, may cause encephalopathy (e.g. impairment of consciousness, abnormal movements and convulsions). Patients should be advised not to drive or operate machinery if any such symptoms occur.

SUMMARY OF PRODUCT CHARACTERISTICS

Cefotaxime for Injection USP 1 g



4.8 Undesirable effects

System organ class	Very common ($\geq 1/10$)	Common ($\geq 1/100$ to $<1/10$)	Uncommon ($\geq 1/1,000$ to $<1/100$)	Rare ($\geq 1/10,000$ to $<1/1,000$)	Very rare ($<1/10,000$)	Not known (cannot be estimated from available data)*
Infections and infestations						Superinfection
Blood and the lymphatic system disorders			Leukopenia Eosinophilia Thrombocytopenia			Neutropenia Granulocytopenia Agranulocytosis Haemolytic anaemia
Immune system disorders			Jarisch-Herxheimer reaction			Anaphylactic reactions Angioedema Bronchospasm Anaphylactic shock
Nervous system disorders			Convulsions			Headache Dizziness Encephalopathy (e.g. impairment of consciousness, abnormal movements)
Cardiac disorders						Arrhythmia following rapid bolus infusion through central venous catheter
Gastrointestinal disorders			Diarrhoea			Nausea Vomiting Abdominal pain Pseudomembranous colitis
Hepato-biliary disorders			Increase in liver enzymes (ALAT, ASAT, LDH, gamma-GT and/or alkaline phosphatase) and/or bilirubin			Hepatitis* (sometimes with jaundice)
Skin and subcutaneous disorders			Rash Pruritus Urticaria Drug fever			Erythema multiforme Stevens-Johnson syndrome Toxic epidermal necrolysis
Renal and Urinary disorders			Decrease in renal function/increase of creatinine (particularly when co-prescribed with aminoglycosides)			Interstitial nephritis Candidiasis
General disorders and administration site conditions	For IM formulations: Pain at the injection site		Fever Inflammatory reactions at the injection site, including phlebitis / thrombophlebitis			For IM formulations (since the solvent contains lidocaine): Systemic reactions to lidocaine

SUMMARY OF PRODUCT CHARACTERISTICS

Cefotaxime for Injection USP 1 g



* postmarketing experience

Jarisch-Herxheimer reaction

For the treatment of borreliosis, a Jarisch-Herxheimer reaction may develop during the first days of treatment.

The occurrence of one or more of the following symptoms has been reported after several week's treatment of borreliosis: skin rash, itching, fever, leucopenia, increase in liver enzymes, difficulty of breathing, joint discomfort.

Hepatobiliary disorders

Increase in liver enzymes (ALAT, ASAT, LDH, gamma-GT and/or alkaline phosphatase) and/or bilirubin have been observed. These laboratory abnormalities may rarely exceed twice the upper limit of the normal range and elicit a pattern of liver injury, usually cholestatic and most often asymptomatic.

4.9 Overdose

Symptoms of overdose may largely correspond to the profile of side effects.

There is a risk of reversible encephalopathy in cases of administration of high doses of β -lactam antibiotics including cefotaxime.

In case of overdose, cefotaxime must be discontinued, and supportive treatment initiated, which includes measures to accelerate elimination, and symptomatic treatment of adverse reactions (e.g. convulsions).

No specific antidote exists. Serum levels of cefotaxime may be reduced by peritoneal dialysis or haemodialysis.

5. Pharmacological Properties

5.1 Pharmacodynamic Properties

ATC Classification: Pharmacotherapeutic group: Beta-lactam antibiotics, cephalosporins.

ATC Code: J01D A10

Mode of action

Cefotaxime is a third generation broad spectrum bactericidal cephalosporin antibiotic. The bactericidal properties are due to the inhibitory effect of cefotaxime on bacterial cell wall synthesis.

SUMMARY OF PRODUCT CHARACTERISTICS

Cefotaxime for Injection USP 1 g



Mechanisms of resistance

Resistance to Cefotaxime may be due to production of extended-spectrum beta-lactamases that can efficiently hydrolyse the drug, to the induction and/or constitutive expression of AmpC enzymes, to impermeability or to efflux pump mechanisms. More than one of these possible mechanisms may co-exist in a single bacterium.

5.2 Pharmacokinetic Properties

After a 1000 mg intravenous bolus, mean peak plasma concentrations of cefotaxime usually range between 81 and 102 microgram/ml. Doses of 500 mg and 2000 mg produce plasma concentrations of 38 and 200 microgram/ml, respectively. There is no accumulation following administration of 1000mg intravenously or 500mg intramuscularly for 10 or 14 days.

The apparent volume of distribution at steady-state of cefotaxime is 21.6 litres/1.73m² after 1g intravenous 30 minute infusion.

Concentrations of cefotaxime (usually determined by non-selective assay) have been studied in a wide range of human body tissues and fluids. Cerebrospinal fluid concentrations are low when the meninges are not inflamed, but are between 3 and 30 microgram/ml in children with meningitis. Cefotaxime usually passes the blood-brain barrier in levels above the minimum inhibitory concentration of common sensitive pathogens when the meninges are inflamed. Concentrations (0.2-5.4 microgram/ml), inhibitory for most Gram-negative bacteria, are attained in purulent sputum, bronchial secretions and pleural fluid after doses of 1 or 2g. Concentrations likely to be effective against most sensitive organisms are similarly attained in female reproductive organs, otitis media effusions, prostatic tissue, interstitial fluid, renal tissue, peritoneal fluid and gall bladder wall, after usual therapeutic doses. High concentrations of cefotaxime and desacetyl-cefotaxime are attained in bile.

Cefotaxime is partially metabolised prior to excretion. The principal metabolite is the microbiologically active product, desacetyl-cefotaxime. Most of a dose of cefotaxime is excreted in the urine - about 60% as unchanged drug and a further 24% as desacetyl-cefotaxime. Plasma clearance is reported to be between 260 and 390ml/minute and renal clearance 145 to 217 ml/minute.

After intravenous administration of cefotaxime to healthy adults the elimination half-life of the parent compound is 0.9 to 1.14 hours and that of the desacetyl metabolite, about 1.3 hours.

In neonates the pharmacokinetics are influenced by gestational and chronological age, the half-life being prolonged in premature and low birth weight neonates of the same age.

In severe renal dysfunction the elimination half-life of cefotaxime itself is increased minimally to about 2.5 hours, whereas that of desacetyl-cefotaxime is increased to about 10 hours. Total urinary recovery of cefotaxime and its principal metabolite decreases with reduction in renal function.

SUMMARY OF PRODUCT CHARACTERISTICS

Cefotaxime for Injection USP 1 g



5.3 Preclinical Safety data

There are no preclinical safety data of relevance to the prescriber that are additional to those included in other sections.

6 Pharmaceutical Particulars

6.1 List of Excipients: None

6.2 Incompatibility

Cefotaxime sodium should not be mixed with alkaline solutions such as sodium bicarbonate injection or solutions containing aminophylline.

Cefotaxime should not be admixed with aminoglycosides. If they are used concurrently they should be administered in separate sites.

6.3 Shelf Life

36 Months

6.4 Special Precaution for storage

Store in a dry place at temperature below 30°C.
Keep all medicines out of the reach of children.

6.5 Nature and contents of container

Cefotaxime for Injection USP 1g is supplied in 10mL Type III clear, transparent glass vial with gray coloured bromo butyl rubber stopper and Aluminium flip-off seal with colored polypropylene disc.

1 vial +10 ml SWFI in a mono-carton with pack insert

6.6 Special precautions for disposal and other handling

For single use only. Discard any unused contents.

When dissolved in Water for Injections, cefotaxime forms a straw-coloured solution suitable for intravenous and intramuscular injection. Variations in the intensity of colour of the freshly prepared solutions do not indicate a change in potency or safety.

Dilution table (Intramuscular administration):

Vial size	Diluent	Withdrawable Volume	Approx displacement volume
1g	3 ml	3.4 ml	0.4 ml

SUMMARY OF PRODUCT CHARACTERISTICS

Cefotaxime for Injection USP 1 g



Intravenous administration:

Vial size	Diluent	Withdrawable Volume	Approx displacement volume
1g	10 ml	10.4 ml	0.4 ml

Reconstituted solution: Whilst it is preferable to use only freshly prepared solutions for both intravenous and intramuscular injection, cefotaxime is compatible with several commonly used intravenous infusion fluids and will retain satisfactory potency for up to 24 hours refrigerated (2°-8°C) in sterile water for injections

7 Market Authorization Holder

GB Pharma Limited
65, Chatsworth Road, London NW2 4BG

8 Market Authorization Number(s)

Not Applicable

9 Date of first authorization/Renewal of the authorization

Not Applicable

10 Date of Revision of text

Not Applicable